| Metric | Q2'26 | Q3'26 | Change |
|---|---|---|---|
| Revenue | $112B | $113B | +~1% QoQ, modest |
| Adjusted EPS | $6.38 vs $4.08 PY | $4.69 vs $2.92 PY | +60.6% YoY but down sequentially (different quarters) |
| Consolidated MCR | 86.7% (incl. $860M favorable PPD) | 88.4% vs 89.9% PY | +170bps sequentially, better YoY |
| FY adj. EPS guidance | $19.50-$20.00 | At least $20.50 | Floor raised $1.00; $0.50 above prior range ceiling |
| Debt-to-cap ratio | 41.2%, -170bps sequential | 41.7% | +50bps sequentially, deleveraging reversed |
| Share repurchases YTD | $4B through mid-July; FY target ≥$5B (from $2.5B) | $5B through Q3 | Reported repurchases reach the stated full-year minimum |
| Medicaid margin (FY26) | -1% to -1.7% | Moderately better than -1% | Upward revision |
| Medicare margin (FY26) | Above 3% | Near top end of 2%-4% range | Upward revision toward ~4% |
| Commercial medical trend | Modestly above 11% | Exceeding initial 11% expectation | Still above 11%; no precise updated rate given |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.